Gilead Announces SVR12 Rates from Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV
Seattle, February 26, 2015 – Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from a Phase 3 study, ION-4, evaluating the once-daily…